Aquavit Files Investigational New Drug Application for its Flagship Intradermal Injection of Botulinum Toxin

NEW YORK, April 28, 2023 /PRNewswire/ — Aquavit Holdings (Aquavit), a biotechnology company focused on the development of botulinum toxin applications, announced today that it has filed an Investigational New Drug Application with the FDA for its flagship intradermal injection of…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.